ID   Lovo-273X17
AC   CVCL_5236
SY   Lovo273X17; 273X17
DR   BTO; BTO_0004144
DR   cancercelllines; CVCL_5236
DR   Wikidata; Q54902898
RX   PubMed=8632910;
RX   PubMed=18600534;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:11998; TP53 (Note=With p.Arg273His).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5237 ! LoVo-92
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 23
//
RX   PubMed=8632910;
RA   Pocard M., Chevillard S., Villaudy J., Poupon M.-F., Dutrillaux B.,
RA   Remvikos Y.;
RT   "Different p53 mutations produce distinct effects on the ability of
RT   colon carcinoma cells to become blocked at the G1/S boundary after
RT   irradiation.";
RL   Oncogene 12:875-882(1996).
//
RX   PubMed=18600534; DOI=10.1080/15257770802145512;
RA   Giovannetti E., Backus H.H.J., Wouters D., Peters G.J.;
RT   "Functional inactivity and mutations of p53 differentially affect
RT   sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate
RT   synthase (TS) by altering TS levels in colorectal cancer cells.";
RL   Nucleosides Nucleotides Nucleic Acids 27:740-745(2008).
//